Next Article in Journal
Macrophage Resistance to Ionizing Radiation Exposure Is Accompanied by Decreased Cathepsin D and Increased Transferrin Receptor 1 Expression
Next Article in Special Issue
Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates
Previous Article in Journal
Sentinel Lymph Node Mapping in Presumed Low- and Intermediate-Risk Endometrial Cancer Management (SLIM): A Multicenter, Prospective Cohort Study in The Netherlands
Previous Article in Special Issue
Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 1
10.3390/cancers15010272
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma

Cancers 2023, 15(1), 272; https://doi.org/10.3390/cancers15010272
by Valentina Evdokimova 1,†, Hendrik Gassmann 2,†, Laszlo Radvanyi 1,* and Stefan E. G. Burdach 2,3,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2023, 15(1), 272; https://doi.org/10.3390/cancers15010272
Submission received: 30 November 2022 / Revised: 23 December 2022 / Accepted: 27 December 2022 / Published: 30 December 2022
(This article belongs to the Special Issue Ewing Sarcoma: Basic Biology, Clinical Challenges and Future Perspectives)

Round 1

Reviewer 1 Report

In this manuscript the authors present a review of the literature on the potential novel immunotherapy strategies and on the mechanisms of immune escape of two subtypes of sarcoma : osteosarcoma and Ewing sarcoma. These two childhood bone cancers are indeed among the leading causes of cancer-related deaths in children. No significant improvement for outcomes has been made for the patients in the last two decades and there is an urgent need to find innovative therapies targeting these tumors and those indeed include immunotherapy strategies.

This is an interesting review, well-written, clearly presented and well-illustrated which provides useful information.

I only have the following minor comments :

-          Although the focus of the review is on osteosarcoma and Ewing sarcoma, since sarcoma represent a highly complex and heterogeneous group of tumors, it would be useful to have a short paragraph replacing these two childhood bone sarcomas in the context of the other sarcomas regarding immunogenicity and immunotherapy approaches.

-          Trabectedin is mispelled : Trabectidin instead of Trabectedin.

-          The disialoganglioside GD2 appears as a promising immunotherapeutic target for osteosarcoma and Ewing sarcoma, it is highly expressed especially in Ewing sarcoma. The authors might therefore develop the potential of this strategy notably the GD2-directed CAR-T cell approach.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

In this review, firstly, historical perspectives and modern immunotherapy in pediatric sarcomas, especially immunotherapy were introduced. Moreover, mechanisms of immune evasion in Ewing sarcoma and osteosarcoma were highlighted. This

review summarizes the cutting-edge immunotherapy in Ewing Sarcoma and Osteosarcoma. However, the manuscript requires minor revisions.

1. I suggest that the authors use a table to illustrate “Immunotherapy of Pediatric Bone Cancers”.

2. I suggest that the author use different colors to distinguish the nucleus from the cytoplasm in Figure 2. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop